#OP0206 #EULAR2026: 🛴SCOOT trial compared oral split-dose vs SC MTX in early active RA. Non-inferiority of split-dose oral MTX was not shown, with several efficacy outcomes favouring SC MTX and more transaminitis seen with oral split dosing. @RheumNow

#OP0205 #EULAR2026: 🌞SUNSTAR head-to-head trial compared SC TOC vs Abatacept after failure of 1-2 b/tsDMARDs in RA. Primary CDAI endpoint was not met, but composite response and treatment persistence favoured tocilizumab. @RheumNow https://t.co/UepvKcbiNJ

• https://x.com/DrMiniDey/status/2063170527234072614/photo/1

Effect of IL-17i on metabolic profile and CV safety in PsA/axSpA 169 pts 12mo -IL-17i no MACE reported -CRP reduced 4.8 → 2.9 mg/L, p<0.001 -79% systemic inflammatory response -Lipids stable (LDL, TG, TC) 12mo follow up is probably too short though #POS0375 #EULAR2026 https://t.co/u6cvB5YYGq

• https://x.com/AurelieRheumo/status/2063165365715140763/photo/1

#OP0204 #EULAR2026 Shared decision-making in practice! BACH study tested “treat by choice” in RA. Patients preferred oral JAKi over SC TNFi (55% vs 45%) Importantly, own choice led to higher treatment satisfaction, better drug survival & fewer adverse events. @RheumNow #EULARBest https://t.co/iI1n2OGzqY

• https://x.com/DrMiniDey/status/2063166752268410881/photo/1

Prospective study of RVZ immunogenicity = heterogeneous cellular immunity across RMDs 12mo 150 pts -CD4+ gE-T-cell response peaks mo 3 -Response seen in axSpA + GCA, but not RA -25% of patients no CMI increase after vaccination Consistent w/other vaccine cellular imm profiles https://t.co/yvDLSHh4Bj

• https://x.com/AurelieRheumo/status/2063164639731417439/photo/1

#OP0203 #EULAR2026: low-dose blinatumomab in multidrug-resistant RA introduced the intriguing concept of “immune dimming”, transient B-cell depletion that appeared to restore responsiveness to previously failed DMARDs, JAK inhibitors and TNFi in several patients. @RheumNow

Frailty as a long term outcome in RA Higher frailty in RA vs ctrls HR 1.76 in 910 matched pairs. -10y: 30.6% vs 19.1% -20y: 53.8% vs 35.3% -Stronger in recent RA (HR 2.38) Driven by age, smoking, comorbidity, steroids/biologics not RF/CCP. Preventive interventions needed https://t.co/pcJrE73G5O

• https://x.com/AurelieRheumo/status/2063163732897693900/photo/1

TRM-SLE is a novel clinical outcome assessmentfor use in #SLE trials 8 domains: mucocutaneous, arthritis, hemolytic anemia, thrombocytopenia, nephropathy, serositis Developed via multistage consensus process Higher pt enrollment potential? POS1068 @RheumNow #EULAR2026 https://t.co/W614xZV7TX

• https://x.com/RHEUMarampa/status/2063162488732934213/photo/1

Catching up on #EULAR2026 “Advanced management in RA” session: #OP0202 reported positive phase 2b RENOIR data for rosnilimab, a selective pathogenic T-cell depleter, with significant improvements in DAS28-CRP, ACR responses and CDAI LDA vs placebo in RA. @RheumNow https://t.co/IKKtakxpya

• https://x.com/DrMiniDey/status/2063161469080846760/photo/1

Machine learning identifies a “vulnerable” phenotype in older RA patients n=275 -51% “vulnerable” -Worse grip strength, gait speed & SARC-F -Higher disability (HAQ 1.56 vs 0.64) -More fatigue, poorer QoL -Higher DAS28 despite greater biologic exposure Suggests we should assess https://t.co/bv1FbTxGKR

• https://x.com/AurelieRheumo/status/2063143217885855817/photo/1

#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi

• 5 years since Patient ID001: Progress on CAR-T Therapy in RMD | RheumNow
• https://x.com/Yuz6Yusof/status/2063141761061400974/photo/1

Depression at RA diagnosis did not predict short-term CV events in a nationwide early RA cohort -17,669 early RA pts -7.3% BL depression -Median follow-up 1.2 years -No association w/ CV hospitalisation after adjustment (sHR 1.05) Reassuring short-term data, longer follow-up https://t.co/XmMVGY1VlI

• https://x.com/AurelieRheumo/status/2063141746825900497/photo/1

How many ‘cars’ are there? crowded #CAR-T ‘driving’ innovation at #EULAR2026 >90 abstracts w CAR-T in title Lessons learned Maybe #immune #reset is not always the goal ➡️vs ’#immune #dimming How long are effects? safety looks good PT selection is key Early, no damage @RheumNow https://t.co/6jii5MBJcJ

• https://x.com/Janetbirdope/status/2063008581935333473/photo/1
• https://x.com/Janetbirdope/status/2063008581935333473/photo/1
• https://x.com/Janetbirdope/status/2063008581935333473/photo/1

One of the highlights of #EULAR2026 for me: ♀️The "This Is a Woman's World" session I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬 https://t.co/3jwJIegGg4 via @YouTube @ArLARheumatolog https://t.co/Azvkl2sjdu

• This Is a Woman’s World: Women's Health in Rheumatic Disease
• https://x.com/Nellziade/status/2062965329496539425/photo/1

Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw

• https://x.com/AurelieRheumo/status/2062950853187695084/photo/1